3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Transitional Cell
6
Urinary Bladder Neoplasms
5
Ureteral Neoplasms
3
Urologic Neoplasms
2
Neoplasm Metastasis
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Peripheral Nervous System Diseases
1
Neoplasms by Site
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Adenocarcinoma of the Bladder
1
Interventions
pembrolizumab
2
enfortumab vedotin
2
Gemcitabine
2
testosterone 17 beta-cypionate
1
temsirolimus
1
Valproic Acid
1
Testosterone Propionate
1
Standard of Care
1
Sirolimus
1
Radiation Dose Hypofractionation
1
Practice Guidelines as Topic
1
Mitomycin
1
Methyltestosterone
1
Immunoglobulin G
1
Fluorouracil
1
Disulfides
1
Cisplatin
1
Cetuximab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
enfortumab vedotin
×
30 days
×
Clear all
NCT05614739
2026-05-19
FORAGER-1
Eli Lilly and Company
Phase 1
Recruiting
535 enrolled
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled